20% discount on all 2013/2014 reports until the 31st of march 2016

We are pleased to announce that IndustryARC Reports published in 2013 and 2014 are now discounted by 20%

The discount will end on the 31st of March 2016. For more information please visit this link

COPD Therapeutics in Major Developed Markets in 2021

The global treatment market for Chronic Obstructive Pulmonary Disease (COPD) will rise steadily from $9.2 billion in 2014 to $11.2 billion in 2021, at a compound annual growth rate of 2.9%. The COPD therapeutics market landscape over the forecast period will be characterized by the sales erosion of leading brands. Currently, the market is dominated by three brands, namely Pfizer’s Spiriva, GlaxoSmithKline’s (GSK’s) Advair and AstraZeneca’s Symbicort, which have all generated multi-billion dollar revenues to date.

The patents for these leading brands have either expired or will do very soon, leaving the market open to generic competition, which will impact negatively on these brands’ sales figures. The market, which used to be dominated by only a few brands, will become more fragmented and will see the introduction of various brands with similar characteristics.

GBI Research’s COPD Therapeutics in Major Developed Markets in 2021 – Emergence of Addition-in-Class and First-in-Class Products Offsets Sales Erosion of Leading Brands report provides analysis of the Chronic Obstructive Pulmonary Disease (COPD) treatment pipeline, by stage of development, molecule type, and molecular target. It provides information on the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in COPD.

Key findings:

  • The COPD market has benefited from notable additions over recent years.
  • The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-in-class therapies.
  • The COPD market is forecast to rise from a value of $9.2 billion in 2014 to $11.2 billion in 2021, at a CAGR of 2.9% across the eight major markets assessed..
  • There have been 59 licensing deals and 41 co-development deals pertaining to COPD products since 2006.

Report Information
Price: $4,995 (Single User License)
Published: Nov- 2015
Report Format: electronic pdf

China Will Face Most Scrutiny at COP21

195 countries and the European Union have consented to a global climate change agreement to limit the rise in global temperature to 2°C by 2100, at the United Nations’ 21st Conference of the Parties (COP21). The major focus areas of the conference included decreasing Greenhouse Gas (GHG) emissions and promoting sustainable development (UNDP, 2015).

China will face most scrutiny, thanks to their ambitious emissions targets, that others view as unrealistic. On 30 June 2015, China put forward its Intended Nationally Determined Contribution (INDC), which aims to attain peak CO2 emissions by or before 2030. China currently stands first in terms of global greenhouse gas emissions, and as a result will play a key role in the outcome of COP21.

Overall, the world is taking seriously the need to assuage the effects of climate change. Despite this, COP21’s biggest obstacle will likely be reaching a committed and legally binding agreement to tackle climate imbalance that works for all countries, particularly considering the financial costs of implementing environmentally-friendly policies.

GlobalData’s COP21 – A Crucial Pathway Towards Attaining a New Universal Climate Agreement, report provides an overview of Intended Nationally Determined Contribution submissions and efforts undertaken by major countries to combat global climatic conditions during the United Nations’ 21st Conference of the Parties (COP21).

 

Reasons to Buy:

  • Gain insight on the INDC submissions by the EU and countries such as Japan, China, India, and the US ahead of the COP21 discussions
  • Understand efforts undertaken by countries to combat global climatic conditions and key happenings ahead of the Paris talks
  • Comprehend the key challenges likely to be encountered ahead of the conference

Report Information
Price: $500 (Single User License)
Published: Dec- 2015
Report Format: electronic pdf

Deals Decreased in the Medical Equipment Industry in Q3 2015

GlobalData’s “Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends – Q3 2015” report is an essential source of data and trend analysis on the mergers and acquisitions (M&As) and financing in the medical equipment market. The report provides detailed information on M&As, equity/debt offerings, private equity, venture financing and partnership transactions registered in the medical equipment industry in Q3 2015. The report discloses detailed comparative data on the number of deals and their value in the past five quarters, categorized into deal types, segments, and geographies. The report provides information on the top private equity, venture capital and advisory firms in the medical equipment industry.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database and primary and secondary research.

M&As Decreased In Q3 2015

Mergers and acquisitions (M&As), including asset transactions, recorded decrease in the number of deals and deal values in Q3 2015 with 142 deals worth $23.1 billion, as compared to 158 deals worth $26.4 billion in Q3 2014. On a quarter-on-quarter basis, the number of deals and deal values increased in Q3 2015, compared to 129 deals worth $21.3 billion in Q2 2015.

Number Of IPOs Decreased In Q3 2015

Global equity offerings, including initial public offerings (IPO), secondary offerings, and private investment in public equities (PIPEs), recorded an increase in the number of deals and deal values with 105 deals worth $4.3 billion in Q3 2015, compared to 54 deals worth $2.4 billion in Q3 2014. On a quarter-on-quarter basis, the number of deals decreased and deal values increased in Q3 2015, compared to 113 deals worth $3.9 billion in Q2 2015.

The IPO market recorded decrease in the number of deals and deal values with eight deals worth $1.5 billion in Q3 2015, compared to 15 deals worth $1.8 billion in Q3 2014. On a quarter-on-quarter basis, the number of IPOs and their values decreased in Q3 2015, compared to 22 deals worth $2.4 billion in Q2 2015. Besides, 37 secondary offerings worth $1.6 billion and 60 PIPE deals worth $1.2 billion were reported in Q3 2015.

Venture Capital Investments Increased In Q3 2015

The venture capital (VC) segment reported 124 deals worth $1.8 billion in Q3 2015, as compared to 220 deals worth $1.6 billion in Q3 2014. On a quarter-on-quarter basis, the number of VC deals reported declined and their values increased in Q3 2015, compared to 172 deals worth $1.7 billion in Q2 2015s.

Khosla Ventures, LLC topped the list of venture financing firms by participating in eight deals worth $213m between Q3 2014 to Q3 2015.

North America Recorded Decline In The Number Of Deals Q3 2015

North America recorded a decrease in the number of deals and an increase in deal values in Q3 2015. The region registered 349 deals worth $40.1 billion in Q3 2015, compared to 447 deals worth $26.3 billion in Q3 2014. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q3 2015, when compared to 406 deals worth $45.6 billion in Q2 2015.

Europe recorded a decrease in the number of deals and deal values in Q3 2015 with 135 deals worth $5.9 billion, as compared to 142 deals worth $25 billion in Q3 2014. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q3 2015, when compared to 160 deals worth $6.2 billion in Q2 2015.

Asia Pacific recorded an increase in the number of deals and deal values in Q3 2015. The region reported 80 deals worth $4.7 billion in Q3 2015, as compared to 65 deals worth $478.3m in Q3 2014. On a quarter-on-quarter basis, the number of deals decreased and deal values increased in Q3 2015, when compared to 85 deals worth $1.7 billion in Q2 2015.

Multiple Sclerosis Treatment Market to Reach $20 Billion by 2024

The main driver of growth in the Multiple Sclerosis (MS) market is the introduction of novel DMT products over the forecast period. Drugs targeting clinical unmet needs; such as improved efficacy, more convenient administration, or progressive MS approval; will increase treatment rates and drive market growth. The biggest barrier for growth in the MS market will be competition from generic/biosimilar products for key branded therapies. In particular, the launch of generic small-molecules will hamper future growth of the MS market. Considerable opportunity remains for products that meet the unmet needs in the MS market. A drug that prevents disease progression and the accumulation of disability would be viewed favourably. Additionally, targeting progressive MS will be an ongoing opportunity.

GlobalData’s PharmaPoint: Multiple Sclerosis – Global Drug Forecast and Market Analysis to 2024 report provides analysis of the multiple sclerosis treatment space across the ten major markets of the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India. It includes annualized market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.

 

The report includes:

 

  • Overview of MS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines

 

  • Annualised MS market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024

 

  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the MS therapeutics market

 

  • Analysis of the current and future market competition in the global MS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

 

The MS market has experienced a paradigm shift with the launch of first-line oral DMTs and efficacious escalation therapies. Are you aware of the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period? Find out more!

Genetic testing trends in BRIC countries

The genetic testing market is growing at a high pace creating new life for the industry. The main factors propelling the BRIC countries are aging population, increase in genetic disorder incidences and rising awareness. The BRIC genetic testing market grew at a CAGR of 14.1% during 2007-2014. The market is forecast to reach $247.3 million in 2021 with a CAGR of 15.4% from 2014-2021.

GlobalData’s BRIC Genetic Testing Market Outlook to 2021 report is a comprehensive report, covering key market data on the BRIC Genetic Testing market.

The report covers:

  • The three main market segments – Inborn Gene or Chromosome Alterations, Acquired Gene or Chromosome Alterations and Other Genetic Tests
  • Annualised market revenues (USD) data for each of the market segments from 2007 to 2014 and forecast to 2021
  • Global corporate-level profiles of key companies operating within the BRIC Genetic Testing Market

What’s the next big thing in the BRIC genetic testing market.. Find out now!

Government delays deepwater bidding after shallow-water disappointment

Petróleos Mexicanos (Pemex) has had a monopoly over the Mexican upstream oil and gas industry since 1938, but the government is now opening up the sector to outside investment in an effort to combat production declines. While the only outside investment in the sector was previously through limited service contracts granted by Pemex, the government will now be able to sign royalty and tax licenses, PSCs, profit-sharing contracts and service contracts with investors.

GlobalData’s Mexico Upstream Fiscal and Regulatory report presents the essential information relating to the terms which govern investment into Mexico’s upstream oil and gas sector. The report sets out in detail the new contractual frameworks introduced under the country’s energy reforms, clearly defining the factors affecting profitability and quantifying the state’s take from hydrocarbon production.

This report includes:

  • An overview of fiscal terms governing upstream oil and gas operations in Mexico
  • Details on the legal framework and governing bodies administering the industry
  • Levels of upfront payments and taxation applicable to oil and gas production
  • Details of the licensing process in ‘Round 1’
  • Explanation of production sharing mechanisms in production sharing agreements

 

Do you have information on the special fiscal regime applicable to Petróleos Mexicanos (PEMEX)? Find out now!

Public companies dominate the ammonia sector in China

Chinese Ammonia plant capacity has increased at a CAGR of 3.5% during 2005-15 and is expected to increase at a rate of 2.4% from to 2019, mainly dominated by public companies. such as China National Petroleum Corporation, China Petroleum & Chemical Corporation, Shanxi Jincheng Anthracite Mining Group Co., Ltd., and Sichuan Lutianhua Company Limited. Together, these companies accounted for 13.9% of the Ammonia capacity in China.

GlobalData’s Ammonia Industry Outlook in China to 2019 – Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants report covers China’s historical and forecast market size, demand and production forecasts, end-use demand details, price trends, trade balance data, and company shares of the country’s leading Ammonia producers.

This report provides:

  • Comprehensive information of major planned & active ammonia projects & plants in China
  • Capacity forecasts to 2019 with operator and equity details
  • Ammonia industry market dynamics and supply scenario in China from 2005 to 2019
  • Company capacity shares for key ammonia producers in China

Get a detailed company overview, business description, information on current and upcoming Ammonia plants for China Petroleum & Chemical Corporation, Shanxi Jincheng Anthracite Mining Group Co., Ltd., and China National Petroleum Corporation.

China expected to lead solar PV installations globally

China will retain its world’s largest market share position for annual solar PV installations, adding around 17.6 GW this year. The US will far behind with 8.2 GW of additions, while India will witness strong demand in its solar PV market thanks to growing policy and political support. However, with Germany implementing initial measures to move away from expensive renewable energy subsidies and towards a reverse auction system by 2017 – will see reduction in installations. Similarly, Japan’s lucrative solar PV policies, which have been attracting strong investments in the recent years, have witnessed cuts that translate into a reduction in installed capacity additions, compared to the preceding record-breaking figure of 10 GW.

 

GlobalData’s Mid-Year Solar Power Market Update report provides analysis of the expected trends in the solar Photovoltaic (PV) market, including the demand-supply scenario in global solar sector, as well as commentaries on the major solar PV countries like Germany, Italy, India, China, Japan and the US.

This report includes:

  • An analysis on expected trends in the solar market
  • The demand-supply scenario in global solar market
  • Key commentaries on the major solar PV markets
  • Reduced solar photovoltaic additions in Germany and Japan will not dampen global growth. Find out how?

QYResearch reports are now available on GlobalMarketAnalyst.com

We are pleased to announce that QYResearch reports are now available on www.globalmarketanalyst.com

Established in 2007, the company focuses on custom research, management consulting, IPO consulting, industry chain research, database and seminar services.

QYResearch has always pursued product quality, adhere to the quality is the soul of business. Through the company’s years of effort and a lot of customer support, QYResearch consulting group creative design method of many high-quality markets investigation and research team with rich experience. Today, QYResearch brand has become the consulting industry with quality assurance consulting brand. The company has 4000 global well-known customers, covering energy automobile pharmaceutical chemical agriculture more than 30 industries, services from the data analysis and recommendations-Consulting landing one-stop solution, and research regions cover China,US,EU,Asia,Middle East and Africa,South America,Australia,etc

Research and marketing centers are available in China(Beijing Shanghai Guangzhou), USA, Canada, Germany, UK, France and Hong Kong. Currently, QYResearch has become the first choice of trusted consulting brand in the global and Chinese business consulting services.

For more information, you can browse QYResearch reports Here